Hydromorphone polymer implant: A potential alternative to methadone maintenance

Deborah Rhodes, Stuart A. Grossman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although methadone maintenance remains the best available treatment for opioid addiction, the need for daily oral dosing limits the effectiveness of methadone as opioid substitution therapy. Limitations of methadone maintenance include the administrative costs and burdensome time commitment associated with daily clinic visits, the danger of illicit diversion and accidental overdose associated with oral dosing, the low rate of treatment retention, and inadequate treatment capacity. A new opioid delivery device awaiting approval for clinical use may overcome some of these limitations. The device, a button-size polymer containing hydromorphone, releases near constant levels of opioid when implanted subcutaneously. Because of its location and duration of effect, the polymer may eliminate the need for daily clinic visits, reduce the costs and time constraints of treatment, reduce the risk of illicit diversion, provide an incentive for compliance with initial methadone maintenance treatment, and increase treatment capacity and retention.

Original languageEnglish (US)
Pages (from-to)535-542
Number of pages8
JournalJournal of Substance Abuse Treatment
Volume14
Issue number6
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Hydromorphone
Methadone
Polymers
Opioid Analgesics
Ambulatory Care
Device Approval
Opiate Substitution Treatment
Therapeutics
Costs and Cost Analysis
Motivation
Equipment and Supplies

Keywords

  • Hydromorphone
  • Intravenous drug use
  • Methadone maintenance
  • Polymer

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Phychiatric Mental Health
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Hydromorphone polymer implant : A potential alternative to methadone maintenance. / Rhodes, Deborah; Grossman, Stuart A.

In: Journal of Substance Abuse Treatment, Vol. 14, No. 6, 01.01.1997, p. 535-542.

Research output: Contribution to journalArticle

@article{cde21d07a0a2472ea50d6831111dffbc,
title = "Hydromorphone polymer implant: A potential alternative to methadone maintenance",
abstract = "Although methadone maintenance remains the best available treatment for opioid addiction, the need for daily oral dosing limits the effectiveness of methadone as opioid substitution therapy. Limitations of methadone maintenance include the administrative costs and burdensome time commitment associated with daily clinic visits, the danger of illicit diversion and accidental overdose associated with oral dosing, the low rate of treatment retention, and inadequate treatment capacity. A new opioid delivery device awaiting approval for clinical use may overcome some of these limitations. The device, a button-size polymer containing hydromorphone, releases near constant levels of opioid when implanted subcutaneously. Because of its location and duration of effect, the polymer may eliminate the need for daily clinic visits, reduce the costs and time constraints of treatment, reduce the risk of illicit diversion, provide an incentive for compliance with initial methadone maintenance treatment, and increase treatment capacity and retention.",
keywords = "Hydromorphone, Intravenous drug use, Methadone maintenance, Polymer",
author = "Deborah Rhodes and Grossman, {Stuart A.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0740-5472(97)00117-7",
language = "English (US)",
volume = "14",
pages = "535--542",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Hydromorphone polymer implant

T2 - A potential alternative to methadone maintenance

AU - Rhodes, Deborah

AU - Grossman, Stuart A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Although methadone maintenance remains the best available treatment for opioid addiction, the need for daily oral dosing limits the effectiveness of methadone as opioid substitution therapy. Limitations of methadone maintenance include the administrative costs and burdensome time commitment associated with daily clinic visits, the danger of illicit diversion and accidental overdose associated with oral dosing, the low rate of treatment retention, and inadequate treatment capacity. A new opioid delivery device awaiting approval for clinical use may overcome some of these limitations. The device, a button-size polymer containing hydromorphone, releases near constant levels of opioid when implanted subcutaneously. Because of its location and duration of effect, the polymer may eliminate the need for daily clinic visits, reduce the costs and time constraints of treatment, reduce the risk of illicit diversion, provide an incentive for compliance with initial methadone maintenance treatment, and increase treatment capacity and retention.

AB - Although methadone maintenance remains the best available treatment for opioid addiction, the need for daily oral dosing limits the effectiveness of methadone as opioid substitution therapy. Limitations of methadone maintenance include the administrative costs and burdensome time commitment associated with daily clinic visits, the danger of illicit diversion and accidental overdose associated with oral dosing, the low rate of treatment retention, and inadequate treatment capacity. A new opioid delivery device awaiting approval for clinical use may overcome some of these limitations. The device, a button-size polymer containing hydromorphone, releases near constant levels of opioid when implanted subcutaneously. Because of its location and duration of effect, the polymer may eliminate the need for daily clinic visits, reduce the costs and time constraints of treatment, reduce the risk of illicit diversion, provide an incentive for compliance with initial methadone maintenance treatment, and increase treatment capacity and retention.

KW - Hydromorphone

KW - Intravenous drug use

KW - Methadone maintenance

KW - Polymer

UR - http://www.scopus.com/inward/record.url?scp=0031465009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031465009&partnerID=8YFLogxK

U2 - 10.1016/S0740-5472(97)00117-7

DO - 10.1016/S0740-5472(97)00117-7

M3 - Article

C2 - 9437625

AN - SCOPUS:0031465009

VL - 14

SP - 535

EP - 542

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 6

ER -